Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AM 401

Next Previous
Drug Profile

AM 401

Alternative Names: AM-401

Latest Information Update: 30 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Auris Medical
  • Developer Altamira Therapeutics
  • Class Antineoplastics; Peptides; Small interfering RNA; Vascular disorder therapies
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Abdominal aortic aneurysm; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 24 Sep 2024 Altamira Therapeutics plans to file an IND application to the US FDA for Cancer in 2026
  • 24 Sep 2024 Altamira Therapeutics announces intention to submit IND application to the US FDA for Cancer in 2026
  • 22 Jul 2024 Pharmacodynamic and adverse events data from a preclinical studies in Abdominal aortic aneurysm released by Altamira Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top